Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer
文献类型：期刊论文
| 作者 | Zhu, Qizhi1,4; Fu, Meng1,3,4; Qi, Jian1,3,4; Xu, Ziming4; Wang, Yongguang3; Wang, Zhipeng1,3,4; Wang, Dan4; Liu, Jiajia4; Du, Ruiping3; Wei, Xin1,4 |
| 刊名 | ISCIENCE
 |
| 出版日期 | 2024-08-16 |
| 卷号 | 27 |
| DOI | 10.1016/j.isci.2024.110413 |
| 通讯作者 | Hong, Bo(bhong@hmfl.ac.cn) ; Xu, Weiping(weipingx@ustc.edu.cn) |
| 英文摘要 | Platinum-based chemo-resistance is the major issue for the treatment of small cell lung cancer (SCLC). The integrative analysis of multi-omics data is a reliable approach for discovering novel biomarkers associated with chemo-resistance. Here, multi-omics integrative analysis and Cox regression found that higher expression of PCDHB4 was associated with poorer survival of SCLC patients who received chemotherapy. PCDHB4 gene was hypomethylated and upregulated in SCLC, which was validated in the levels of promoter methylation, mRNA, and protein expression. Mechanistically, using bulk RNA-seq data, functional enrichment analysis indicated that higher PCDHB4 expression was associated with lower immune infiltration. The analysis of single-cell RNA-seq (scRNA-seq) found that SCLC cells with PCDHB4 expression exhibited the characteristics of stemness and EMT. In addition, the high expression and hypomethylation of PCDHB4 were also significantly associated with poor survival in lung squamous cell carcinoma. In summary, PCDHB4 is a potential prognostic biomarker of platinum-based chemotherapy in SCLC. |
| WOS关键词 | TUMORIGENESIS ; SCLC ; SOX4 ; LINK |
| 资助项目 | National Natural Science Foundation of China[52072360] ; National Natural Science Foundation of China[81872438] ; Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei[2021YL007] ; Collaborative Innovation Program of Hefei Science Center, CAS[2022HSC-CIP015] ; Program of Clinical Medical Translational Research in Anhui Province[202304295107020092] |
| WOS研究方向 | Science & Technology - Other Topics |
| 语种 | 英语 |
| WOS记录号 | WOS:001267976000001 |
| 出版者 | CELL PRESS |
| 资助机构 | National Natural Science Foundation of China ; Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei ; Collaborative Innovation Program of Hefei Science Center, CAS ; Program of Clinical Medical Translational Research in Anhui Province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/136860]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Hong, Bo; Xu, Weiping |
| 作者单位 | 1.Chinese Acad Sci, Hefei Inst Phys Sci, Hefei, Anhui, Peoples R China 2.Univ Sci & Technol China, Affiliated Hosp USTC 1, Gerontol Inst Anhui Prov, Dept Geriatr,Div Life Sci & Med, Hefei, Anhui, Peoples R China 3.Chinese Acad Sci, Hefei Canc Hosp CAS, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Hefei, Anhui, Peoples R China 4.Univ Sci & Technol China, Hefei, Anhui, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhu, Qizhi,Fu, Meng,Qi, Jian,et al. Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer[J]. ISCIENCE,2024,27. |
| APA | Zhu, Qizhi.,Fu, Meng.,Qi, Jian.,Xu, Ziming.,Wang, Yongguang.,...&Xu, Weiping.(2024).Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer.ISCIENCE,27. |
| MLA | Zhu, Qizhi,et al."Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer".ISCIENCE 27(2024). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。